Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pirker-Frühauf, UM; Friesenbichler, J; Urban, EC; Obermayer-Pietsch, B; Leithner, A.
Osteoporosis in Children and Young Adults: A Late Effect After Chemotherapy for Bone Sarcoma.
Clin Orthop Relat Res. 2012; 470(10):2874-2885 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Friesenbichler Jörg
Leithner Andreas
Obermayer-Pietsch Barbara
Rodriguez Ulrike
Urban Ernst-Christian
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 2
| |
Abstract:
Premature bone loss after childhood chemotherapy may be underestimated in patients with bone sarcoma. Methotrexate (MTX), a standard agent in osteosarcoma protocols, reportedly reduces bone mineral density (BMD). The literature, however, has reported cases of BMD reduction in patients with Ewing's sarcoma treated without MTX. Thus, it is unclear whether osteoporosis after chemotherapy relates to MTX or to other factors. We therefore asked whether (1) young patients with a bone sarcoma had BMD reduction, (2) patients treated with MTX had lower BMD, and (3) other factors (eg, lactose intolerance or vitamin D deficiency) posed additional risks for low BMD. We retrospectively reviewed 43 patients with malignancies who had dual-energy x-ray absorptiometry (DEXA) (lumbar, femoral); 18 with Ewing's sarcoma (mean age, 26 +/- A 8 years), and 25 with an osteosarcoma (mean age, 27 +/- A 10 years). The mean time since diagnosis was 8 +/- A 4 years in the group with Ewing's sarcoma and 7 +/- A 5 years in the group with osteosarcoma. At last followup we determined BMD (computing z-scores), fracture rate, and lifestyle, and performed serum analysis. BMD reduction was present in 58% of patients (37% had a z-score between -1 and -2 SD, 21% had a z-score less than -2 SD) in at least one measured site. Seven of the 43 patients (16%) had nontrauma or tumor-associated fractures after chemotherapy. Findings were similar in the Ewing and osteosarcoma subgroups. We found vitamin D deficiency in 38 patients (88%) and borderline elevated bone metabolism; lactose intolerance was present in 16 patients (37%). Doctors should be aware of the possibility of major bone loss after chemotherapy with a risk of pathologic fracture. Vitamin D deficiency, calcium malnutrition, and lactose intolerance may potentiate the negative effects of chemotherapy, and should be considered in long-term patient management. Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Antimetabolites, Antineoplastic - adverse effects
Bone Density - drug effects
Bone Neoplasms - drug therapy
Child -
Female -
Humans -
Male -
Methotrexate - adverse effects
Osteoporosis - chemically induced
Osteosarcoma - drug therapy
Retrospective Studies -
Time Factors -
Young Adult -

© Meduni Graz Impressum